Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on ESPR. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target for the company. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.25.

Esperion Therapeutics Stock Up 1.0 %

Shares of Esperion Therapeutics stock opened at $2.10 on Thursday. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The firm has a market cap of $413.78 million, a PE ratio of -3.28 and a beta of 1.03. The business’s fifty day simple moving average is $2.46 and its 200-day simple moving average is $2.17.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $51.63 million for the quarter, compared to the consensus estimate of $55.44 million. During the same quarter in the previous year, the business earned ($0.37) EPS. As a group, equities analysts expect that Esperion Therapeutics will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in shares of Esperion Therapeutics by 6,560.6% in the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock worth $560,000 after acquiring an additional 248,254 shares during the period. American Century Companies Inc. purchased a new position in shares of Esperion Therapeutics during the second quarter valued at $50,000. Xponance Inc. purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $28,000. Marshall Wace LLP increased its position in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Esperion Therapeutics during the 2nd quarter worth $148,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.